|
Characteristics of the patients according to rate of normalization of prothrombin time, and warfarin therapy |
|||||
| Characteristics |
Normal |
Slow |
All |
Uni-variable p-value |
Multi-variable p-value |
|
|
|||||
| N |
188 |
14 |
202 |
||
| Sex, males (%) |
136(72) |
11(79) |
147(73) |
n.s.‡ |
|
| Age, y* |
69.1(± 10.8) (36–89) |
73.4(± 13.2) (48–93) |
69.4(± 11.0) (36–93) |
0.16 |
0.49 |
| BMI* |
29.2(± 5.5) (17.1–55.1) |
29.0(± 4.3) (22.2–40.1) |
29.2(± 5.4) (17.1–55.1) |
n.s |
|
| Weekly warfarin dose, mg* |
29.7(± 12.3) (6.25–77) |
23.2(± 13.7) (8.75–57.5) |
29.3(± 12.4) (6.25–77) |
0.06 |
0.20 |
| Baseline INR* |
2.6(± 0.5) (2.0–4.2) |
3.2(± 0.6) (2.1–4.3) |
2.7(± 0.5) (2.0–4.3) |
0.0004 |
0.0021 |
| Day of last dose warfarin* (in relation to surgery) |
-6.1(± 0.5) (-8 – -5) |
-6.1(± 0.3) (-7 – -6) |
-6.1(± 0.5) |
n.s. |
|
| Pre-operative creatinine, μmol/L* |
104(± 34) (49–336) |
120(± 41) (65–196) |
105(± 35) (49–336) |
0.09 |
0.40 |
| Known liver disease (%) |
7(3.7) |
1(7.1) |
8(4.0) |
n.s. |
|
| Medication interaction score* |
1.5(± 1.3) (-1 – 5) |
1.4(± 1.4) (0–4) |
1.5(± 1.3) (-1 – 5) |
n.s. |
|
| Number of concomitant drugs* |
7 (± 3) (0–14) |
8 (± 3) (4–16) |
7 (± 3) (0–16) |
n.s. |
|
| Amiodarone medication (%) |
29(15) |
2(14) |
31(15) |
n.s. |
|
| Thyroid hormone treatment (%) |
21(11) |
2(14) |
23(11) |
n.s. |
|
Schulman et al. Thrombosis Journal 2008 6:15 doi:10.1186/1477-9560-6-15 |
|||||